Global Gluten Intolerance Treatment Market is expected to reach US$ 16.18 billion by 2032

(EMAILWIRE.COM, March 01, 2025 ) 𝐌𝐚𝐫𝐤𝐞𝐭 𝐎𝐯𝐞𝐫𝐯𝐢𝐞𝐰:

The Global Gluten Intolerance Treatment Market reached US$ 6.63 billion in 2024 and is expected to reach US$ 16.18 billion by 2032, growing at a CAGR of 11.8% during the forecast period 2025-2032.

Gluten intolerance, also known as non-celiac gluten sensitivity, is a condition where individuals experience symptoms such as abdominal discomfort, bloating, and fatigue after consuming gluten-containing foods, without having celiac disease or a wheat allergy. Unlike celiac disease, gluten intolerance does not cause damage to the small intestine but can still lead to significant discomfort and impact quality of life.

The gluten intolerance treatment market encompasses treatments aimed at alleviating symptoms and improving digestion, including dietary supplements, enzyme therapies, and emerging pharmaceutical options. As more people become aware of gluten intolerance and its symptoms, the market for supportive treatments and management solutions is expanding.

𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐅𝐫𝐞𝐞 𝐒𝐚𝐦𝐩𝐥𝐞: https://www.datamintelligence.com/download-sample/gluten-intolerance-treatment-market

𝐌𝐚𝐫𝐤𝐞𝐭 𝐓𝐫𝐞𝐧𝐝𝐬:

𝐆𝐫𝐨𝐰𝐢𝐧𝐠 𝐃𝐢𝐚𝐠𝐧𝐨𝐬𝐢𝐬 𝐑𝐚𝐭𝐞𝐬: Increased awareness and improved diagnostic tools are leading to higher diagnosis rates of gluten intolerance, fueling demand for treatment options such as enzyme therapies, supplements, and medications.

𝐑𝐢𝐬𝐞 𝐢𝐧 𝐍𝐮𝐭𝐫𝐢𝐭𝐢𝐨𝐧𝐚𝐥 𝐒𝐮𝐩𝐩𝐥𝐞𝐦𝐞𝐧𝐭𝐬: Enzyme supplements and probiotics are becoming a popular choice due to their non-invasive nature and effectiveness in alleviating gluten-related symptoms.

𝐄𝐱𝐩𝐚𝐧𝐬𝐢𝐨𝐧 𝐨𝐟 𝐆𝐥𝐮𝐭𝐞𝐧-𝐅𝐫𝐞𝐞 𝐏𝐫𝐨𝐝𝐮𝐜𝐭 𝐀𝐯𝐚𝐢𝐥𝐚𝐛𝐢𝐥𝐢𝐭𝐲: The growing number of gluten-free food options and dietary supplements in mainstream markets is driving increased consumer interest and market growth.

𝐄𝐦𝐞𝐫𝐠𝐢𝐧𝐠 𝐏𝐡𝐚𝐫𝐦𝐚𝐜𝐞𝐮𝐭𝐢𝐜𝐚𝐥 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧𝐬: Companies are investing in new drug therapies aimed at addressing gluten intolerance beyond dietary management.

𝐌𝐚𝐫𝐤𝐞𝐭 𝐒𝐞𝐠𝐦𝐞𝐧𝐭𝐚𝐭𝐢𝐨𝐧:

By Treatment Type: Dietary Management, Pharmaceuticals, Nutritional Supplements, Others.

By Patient Type: Pediatric, Adult, Geriatric.

By Formulation: Tablets, Powders, Liquid.

By Distribution Channel: Online Pharmacies, Retail Pharmacies, E-Commerce.

By Region; North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐟𝐨𝐫 𝐂𝐮𝐬𝐭𝐨𝐦𝐢𝐳𝐚𝐭𝐢𝐨𝐧: https://www.datamintelligence.com/customize/gluten-intolerance-treatment-market

𝐆𝐞𝐨𝐠𝐫𝐚𝐩𝐡𝐢𝐜𝐚𝐥 𝐀𝐧𝐚𝐥𝐲𝐬𝐢𝐬:

North America is expected to dominate the gluten intolerance treatment market due to high awareness, advanced healthcare infrastructure, and a large consumer base actively seeking treatment options. The U.S. leads in both diagnosis rates and adoption of treatments, with a growing number of patients opting for enzyme supplements and emerging therapies.

Additionally, the presence of key pharmaceutical companies and the increasing availability of gluten-free products and treatments further strengthen North America’s market share. For instance, in December 2024, GluteGuard, the first clinically proven product in Canada to help protect against accidental gluten ingestion, became widely available, contributing to regional market growth.

𝐂𝐨𝐦𝐩𝐞𝐭𝐢𝐭𝐢𝐯𝐞 𝐋𝐚𝐧𝐝𝐬𝐜𝐚𝐩𝐞:

Major global players in the gluten intolerance treatment market include:

DSM-Firmenich
Genetic Nutrition
NOW Foods
Enzymedica
AMYRA Biotech AG
KLAIRE LABS
Precigen
Takeda Pharmaceutical Company Limited

Companies are focusing on product innovation, clinical trials, and strategic partnerships to expand their presence in the growing market. For example, in October 2024, AMYRA Biotech AG announced the publication of a clinical proof-of-principle study on its lead product AMYNOPEP, the first and only gluten-digesting enzyme combination supporting endogenous digestive enzymes in the small intestine.